Oral and mucocutaneous lichen planus Skin and Connective Tissue Diseases
Conditions
Interventions
1. Assess salivary biomarkers in OLP and MCLP
2. Compare the levels of these biomarkers in the studied groups with healthy controls
3. Correlation of the salivary biomarkers with their clinical manife
Sponsors
University of Sulaimani
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients who are thoroughly informed about the trial and willing to participate 2. Both sexes (male and female), and females not pregnant 3. Oral lichen planus (OLP) and mucocutaneous lichen planus (MCLP) will be clinically and histopathologically confirmed by a dermatologist 4. All the patients not receiving disease-modifying treatment for at least 1 month before the study like corticosteroids and immunosuppressive drugs
Exclusion criteria
Exclusion criteria: 1. Patients who refuse to participate 2. The study excluded patients with other diagnosed oral mucosal diseases and some systemic diseases, including hematological and infectious diseases, and patients with allergic conditions 3. Systemic diseases that induce lichenoid drug eruption like cardiovascular and endocrine diseases 4. Patients who had received topical or systemic treatment 1 month before the study 5. Newly diagnosed cases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured at a single timepoint: 1. Salivary levels of interleukin-6 (IL-6) measured using enzyme-linked immunosorbent assay (ELISA) 2. Salivary levels of interleukin 1-beta (IL-1ß) measured using enzyme-linked immunosorbent assay (ELISA) 3. Salivary levels of interferon-gamma (IFN-?) measured using enzyme-linked immunosorbent assay (ELISA) 4. Disease severity assessed using clinical scoring Lichen Planus Severity Scales: 4.1. For oral lichen planus (OLP): Thongprasom Clinical Score (0-5 scores) 4.2. For cutaneous lichen planus: Physician Global Assessment (PGA) 4.3. Visual Analog scale (VAS) for symptoms in both | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Correlation between salivary cytokine levels and clinical manifestations of oral lichen planus assessed by statistical analysis of ELISA results and clinical scores at completion of data collection 2. Comparison of inflammatory marker profiles between oral-only lichen planus and mucocutaneous lichen planus using statistical analysis of cytokine levels at completion of data collection | — |
Countries
Iraq
Contacts
Public ContactPardis Hama
Outcome results
None listed